Remission of refractory Crohn's disease with anti‐IL‐12/23 therapy in a patient undergoing hemodialysis: A case report

Abstract

Crohn's disease is a relapsing chronic inflammatory condition of the intestine with increasing prevalence around the world. Biologic therapies are currently widely used and have proved safe and effective in treating moderate to severe Crohn's disease. However, contemporary bibliography contains little information about the use of these drugs in patients with end-stage renal disease undergoing hemodialysis. Here we present a case of a 47-year-old female patient with treatment-refractory Crohn's disease on hemodialysis. In this patient, treatment with the anti-IL-12/23 receptor antibody ustekinumab was effective in inducing and maintaining remission while being safe in administering throughout hemodialysis.

Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

“…To‐date, data pertaining to the use of advanced IBD therapies in patients with ESRD with(out) dialysis is scare; with case reports dominating the published literature. These have described the safe and effective use, across varying inflammatory diseases, of monoclonal antibodies such as infliximab, adalimumab, ixekizumab, secukinumab, and ustekinumab in patients with ESRD, including patients requiring dialysis 12 . However, patients with coexisting IBD and CKD, particularly those with ESRD, have traditionally been excluded from clinical trials, accentuating the need for publish data to assist clinicians and inform clinical practice.…”